Press release
Cancer Biomarkers Market Size Expected to Hit US$ 48,438 Million by 2035, exhibiting 13% CAGR: Fact.MR Analysis
Cancer Biomarkers Market
The sharp surge is due to the growing demand for early diagnosis techniques and individualized medicine strategies using biomarker-based diagnostic tests to personalize cancer treatment for patients. Advances in proteomics, genomics, and digital pathology have supported the development of highly sensitive and specific biomarkers.
For More Insights into the Market, Request a Sample of this Report:
https://www.factmr.com/connectus/sample?flag=S&rep_id=4587
Country-wise Analysis
The U.S. cancer biomarkers market is anticipated to grow at 10.1% CAGR during the forecast period. As a global precision medicine and oncology research leader, the U.S. has built a strong platform for developing and implementing cancer biomarkers.
UK cancer biomarkers market is anticipated to grow at 9.0% CAGR over the forecast period. Growing interest in the early-stage diagnosis of cancer and the country-wide drive toward precision medicine is fueling adoption toward biomarker-based diagnostics.
The French market for cancer biomarkers will expand at an 8.5% CAGR over the forecast period. Personalized medicine has been a priority in France through national cancer plans, and this has fostered a favorable research and implementation environment for cancer biomarkers. Molecular profiling of cancer treatment guidelines is becoming more standardized, particularly in breast, lung, and colorectal cancers.
Italy will grow at 8.1% CAGR over the study period. Increasing incidence of cancer and increasing emphasis on value-based care are driving the application of cancer biomarkers in Italy. The use of molecular diagnostics in country guidelines for cancer treatment has increased with more importance, especially for the management of colorectal, breast, and lung cancer.
The South Korean cancer biomarkers market will grow at a 7.7% CAGR through the study period. Government focus on biotechnology and medical device innovation is driving the uptake of sophisticated diagnostic solutions, such as cancer biomarkers. Personalized medicine is being aggressively implemented across public healthcare facilities in South Korea, with additional hospitals embracing molecular and genomic tests.
Segment-wise Analysis
By Test Type
The market for cancer biomarkers is categorized on the basis of test type, where PSA (Prostate-Specific Antigen) Tests and CA (Cancer Antigen) Tests are the most commonly used diagnostic tests. The PSA tests segment will have an estimated share of approximately 12% by 2025, whereas CA tests have about 11%.
By Disease Indication
Under disease indications, the cancer biomarkers market has lung cancer and breast cancer segments. 18% of the market is commanded by breast cancer and 20% by lung cancer.
Competitive Outlook
The cancer biomarkers market is intensely competitive because there are many diversified diagnostics firms, pharma titans, and genomics revolutionaries present.
Post-2024, competition is intensifying around the ideas of biomarker-based precision medicine, companion diagnostics, and MCED (multi-cancer early detection) panels. F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Illumina, Inc., QIAGEN, and Abbott Laboratories are a few of the dominant players who rule the landscape through varied molecular diagnostics portfolios and wide-ranging research collaborations.
These diagnostics include companion diagnostics, biomarker discovery, and liquid biopsy solutions as part of its oncology diagnostics business.
Roche also leverages synergies across its pharmaceutical and diagnostics businesses to accelerate drug development with biomarkers. Thermo Fisher Scientific enhances its competitive advantage through next-gen sequencing (NGS) platforms, the scope of biomarker assay offerings, and acquisition tactics that enhance its oncology diagnostic capabilities.
Illumina has been among the pioneering firms in genomic sequencing and, therefore, would act as a foundation for biomarker discovery using its high-throughput platforms.
As a result of the mounting pressure on developing new methods for early detection of cancers, Illumina also collaborated with other diagnostic developers seeking strategic alliances in this area. QIAGEN manufactures PCR- and NGS-based tests and has robust partnerships with pharmaceutical firms, which helped it establish a strong position in companion diagnostics.
Browse Full Report: https://www.factmr.com/report/4587/cancer-biomarkers-market
Key Players
Abbott Laboratories
Merck & Co., Inc.
Thermo Fisher Scientific Inc.
Illumina, Inc.
bioMérieux SA
QIAGEN
Agilent Technologies, Inc.
Hologic, Inc.
Novartis AG
F. Hoffmann-La Roche Ltd.
Genomic Health, Inc.
Segmentation
By Test Type :
PSA Tests
CTC Tests
AFP Tests
CA Tests
HER2 Tests
BRCA Tests
ALK Tests
CEA Tests
EGFR Mutation Tests
KRAS Mutation Tests
Others
By Disease Indication :
Breast Cancer
Lung Cancer
Colorectal Cancer
Melanoma
Blood Cancer
Prostate Cancer
Ovarian Cancer
Stomach Cancer
Liver Cancer
Others
By Region :
North America
Europe
Asia Pacific
Latin America
Check out More Related Studies Published by Fact.MR:
Exosome Research Products Market
https://www.factmr.com/report/exosome-research-products-market
Actigraphy Sensors & PSG Devices Market
https://www.factmr.com/report/2829/actigraphy-sensors-psg-devices-market
Dental 3D Printing Market
https://www.factmr.com/report/4361/dental-3d-printing-market
Veterinary Artificial Insemination Market
https://www.factmr.com/report/veterinary-artificial-insemination-market
Contact:
US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583, +353-1-4434-232
Email: sales@factmr.com
About Fact.MR
We are a trusted research partner of 80% of fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client's satisfaction.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Cancer Biomarkers Market Size Expected to Hit US$ 48,438 Million by 2035, exhibiting 13% CAGR: Fact.MR Analysis here
News-ID: 3989819 • Views: …
More Releases from Fact.MR
Liquid Biopsy Market to Hit USD 24.70 Billion by 2033 | Key Players Covered: Bio …
The global liquid biopsy market size is estimated at US$ 4.72 billion in 2023 and is forecasted to expand rapidly at a CAGR of 18% to reach a valuation of US$ 24.70 billion by 2033, according to a newly released market study of liquid biopsy by Fact.MR, a market research and competitive intelligence provider. This growth is driven by the increasing demand for non-invasive cancer diagnostics, advancements in next-generation sequencing…
Artificial Kidney Market is Growing at a CAGR of 13% by 2033 | Key Players: Kawa …
Artificial Kidney Market is valued at USD 1.5 billion in 2023 and is projected to surge ahead at a CAGR of 13% to reach a market size of USD 5.3 billion by the end of 2033. This robust growth is driven by the increasing prevalence of chronic kidney disease (CKD) and end-stage renal disease (ESRD), affecting millions worldwide, and the limitations of current dialysis treatments. Artificial kidneys, including wearable and…
Artificial Intelligence (AI) in Retail Market is Projected to Reach USD 138.3 Bi …
The global artificial intelligence (AI) in retail market is forecast to reach USD 138.3 billion by 2035, up from USD 9.8 billion in 2025. During the forecast period, the industry is projected to register at a CAGR of 30.3%. AI-driven personalization enhances customer engagement through tailored recommendations and experiences. AI-powered demand forecasting optimizes inventory management and reduces operational inefficiencies. This rapid expansion is fueled by the increasing adoption of AI…
Mining Automation Market is Expected to Reach USD 8.4 Billion by 2035 | Fact.MR …
The global mining automation market is forecast to reach USD 8.4 billion by 2035, up from USD 4.5 billion in 2025. During the forecast period, the industry is projected to register at a CAGR of 6.4%. This growth is driven by the increasing demand for minerals, the need for sustainable and low-emission operations, labor shortages, and enhanced safety in hazardous environments. Technological advancements in AI, IoT, robotics, and digital twins…
More Releases for Test
Vitamin Test Market: Global Vitamin Test Analysis and Forecast (2023-2029)Vitami …
12.04.2024: Vitamin Test Market Overview
The development of companion diagnostic tools and advances in personalised treatment are driving considerable growth and revolution in the oncology Vitamin Test market. In the era of precision medicine, where healthcare is increasingly customised for individual individuals based on their own genetic and molecular profiles, this market segment is essential. Ongoing innovation and development define the oncology Vitamin Test market. To find particular biomarkers, genetic mutations,…
CAGR 8.1% Homecare Pregnancy Test Kits Market By Type of Test (Urine Test For H …
The Homecare Pregnancy Test Kits market report by Reports and Data provides an extensive overview of the vital elements of the Homecare Pregnancy Test Kits market and factors such as the drivers, restraints, latest trends, supervisory scenario, competitive landscape, technological advancements, and others. Further, it mentions the market shares associated with the market in terms of both value and volume along with the segmentation. Space-age industrial and digitalization tools are…
Home Safety Test Kits Market, Home Safety Test Kits Market Trends, Home Safety T …
“Home Safety Test Kits Market” 2020-2025 Research Report is a professional and in-depth study on the current state of the market. Global Home Safety Test Kits market containing a complete view of the market size, business share, profit estimates, SWOT analysis and the regional landscape of the Industry. The report explains key challenges and future development prospects of the market. The Global Home Safety Test Kits analysis is provided for…
Test Data Management (TDM) Market - test data profiling, test data planning, tes …
The report categorizes the global Test Data Management (TDM) market by top players/brands, region, type, end user, market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
This report studies the global market size of Test Data Management (TDM) in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption…
Hearing Screening and Diagnostic Devices Market Demands with Major Tests: pure T …
New Market Research Reports Title "Hearing Screening And Diagnostic Devices Market 2018" Has Been Added to Crystal Market Research Report database.
Hearing Screening and Diagnostic Devices - Competitive Insights:
The leading players in the market are Gn Otometrics A/S, Otodynamics, Nashua Hearing Group, Siemens Healthineers, Natus Medical Incorporated, Interacoustics A/S, Neurosoft S.A, Accent Hearing Pty Ltd, MAICO Diagnostics GmbH and IntriCon Corporation. The major players in the market are profiled in detail…
Global Low Temperature Test Equipment Market Outlook 2017 : Ektron Tek, IEC Test …
Global Low Temperature Test Equipment Market 2017-2022
A market study ” Global Low Temperature Test Equipment Market ” examines the performance of the Low Temperature Test Equipment market 2017. It encloses an in-depth Research of the Low Temperature Test Equipment market state and the competitive landscape globally. This report analyzes the potential of Low Temperature Test Equipment market in the present and the future prospects from various angles in detail.
The Global…
